NeOnc reports 12.5% response rate in updated Phase 2a NEO100 glioma trial
NTHI•NeOnc reported a 12.5% response rate in updated Phase 2a results for NEO100 in recurrent or progressive high-grade glioma, including an additional partial response.
NTHI•NeOnc reported a 12.5% response rate in updated Phase 2a results for NEO100 in recurrent or progressive high-grade glioma, including an additional partial response.
NeOnc reported an additional partial response to intranasal NEO100 in patients with recurrent or progressive high-grade glioma. The findings improved on topline results released Aug. 12, 2026, and most patients experienced tumor shrinkage or stable disease.
Reported treatment-related side effects were mild or moderate, with no treatment-related serious adverse events or treatment discontinuations. The trial had no randomized control group, limiting comparisons with other treatments.